<DOC>
	<DOCNO>NCT00461266</DOCNO>
	<brief_summary>This 2 arm study assess immunological benefit add Fuzeon antiretroviral regimen HIV-infected , Fuzeon-naive patient CD4 cell count &lt; 250 cells/mm3 HIV RNA viral load &lt; 400 copies/mL . Eligible patient randomize receive Fuzeon 90mg bid sc addition current antiretroviral therapy , continue current antiretroviral therapy alone . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>ESP Study : A Study Assess Effect Adding Fuzeon ( Enfuvirtide ) Antiretroviral Regimen Fuzeon-Naive Patients With Sustained HIV Viral Suppression .</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; document chronic HIV infection ; currently receive stable antiretroviral regimen ; CD4 cell count &lt; 250 cells/mm3 ; HIV RNA viral load &lt; 400 copies/mL &gt; 12 month . prior exposure Fuzeon ; prior nonadherence antiretroviral treatment regimen ; active opportunistic infection ; currently take , anticipated take study , immunomodulator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>